Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-629: Pembrolizumab in Advanced cSCC
NCT03284424Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2017
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 32 months. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03284424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284424.